Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.

Crowe JE, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR
J Infect Dis. 1998 177 (4): 1073-6

PMID: 9534985 · DOI:10.1086/517397

A second human respiratory syncytial virus (RSV)-neutralizing monoclonal antibody was isolated and its binding site was identified. Fab F2-5 is a broadly reactive fusion (F) protein-specific recombinant Fab generated by antigen selection from a random combinatorial library displayed on the surface of filamentous phage. In an in vitro plaque-reduction test, the Fab RSVF2-5 neutralized the infectivity of a variety of field isolates representing viruses of both RSV subgroups A and B. The Fab recognized an antigenic determinant that differed from the only other human anti-F monoclonal antibody (RSV Fab 19) described thus far. A single dose of 4.0 mg of Fab RSVF2-5/kg of body weight administered by inhalation was sufficient to achieve a 2000-fold reduction in pulmonary virus titer in RSV-infected mice. The antigen-binding domain of Fab RSVF2-5 offers promise as part of a prophylactic regimen for RSV infection in humans.

MeSH Terms (21)

Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Viral Antigens, Viral Female HN Protein Immunoglobulin Fab Fragments Lung Mice Mice, Inbred BALB C Molecular Sequence Data Neutralization Tests Polymerase Chain Reaction Recombinant Fusion Proteins Respiratory Syncytial Virus, Human Respiratory Syncytial Virus Infections Sequence Analysis, DNA Specific Pathogen-Free Organisms Viral Envelope Proteins Viral Proteins

Connections (1)

This publication is referenced by other Labnodes entities: